Demant (DEMANT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
29 Dec, 2025Executive summary
Reported revenue grew 4% in 2024, with 2% organic growth and 2% from acquisitions, reaching DKK 22.4 billion.
Gross profit improved by 5%, but EBIT declined by DKK 100 million (2%) year-over-year, mainly due to exchange rates and lower operating leverage.
Strong cash flow generation, with cash flow from operations at DKK 4 billion and free cash flow at DKK 3.5 billion for the year.
Divestment of CI and communication businesses to focus on core hearing healthcare, with both delivering positive profit in Q4.
Sustainability progress includes reduced emissions and increased gender diversity in leadership, with new and updated targets launched.
Financial highlights
FY 2024 revenue reached DKK 22,419 million, up 4% year-over-year; gross profit rose 5% to DKK 17,090 million.
Gross margin improved by 0.6 percentage points to 76.2%, driven by favorable business mix and strong ASP in hearing aids.
EBIT before special items was DKK 4,404 million (down 2% year-over-year), with EBIT margin at 19.6%.
Share buybacks totaled DKK 2.3 billion for the year.
Net interest-bearing debt ended at DKK 13.5 billion, with a gearing multiple of 2.3x.
Outlook and guidance
2025 organic revenue growth expected at 3%-7%, with EBIT before special items of DKK 4.5-4.9 billion.
Share buyback planned above DKK 1.5 billion.
Acquisitive growth expected at 2%, and currency impact to add 1% to top line.
Effective tax rate expected around 23%.
Market unit growth for hearing aids anticipated at 4-6% with flat ASP; French market expected to grow high single digits.
Latest events from Demant
- 15% revenue growth and upgraded outlook, fueled by acquisitions, cost savings, and innovation.DEMANT
Q2 2026 - Q1 2026 saw 6% organic growth, strong Hearing Aids and Oticon Zeal momentum, and improved profitability.DEMANT
Q1 2026 - 2026 outlook: 3%-6% organic growth, DKK 4.1-4.5bn EBIT, cost savings, Zeal and KIND drive gains.DEMANT
Q4 2025 - Flat organic growth, margin contraction, and revised outlook amid KIND acquisition and market headwinds.DEMANT
Q2 2025 - Q3 organic growth reached 2%, driven by Hearing Care, with 2024 guidance reaffirmed.DEMANT
Q3 2024 - H1 2024 revenue up 4%, gross margin 76.8%, EBIT before special items down 4%.DEMANT
Q2 2024 - €700M acquisition expands clinics to 4,500+, boosts German leadership and revenue growth.DEMANT
M&A Announcement (Media) - EUR 700M acquisition secures German leadership, with synergies and EPS accretion expected.DEMANT
M&A Announcement - 2025 outlook cut as US market weakness and FX headwinds hit growth and earnings.DEMANT
Q1 2025